Trudhesa was approved in September to treat migraine.
Formulary Watch
Latest News
All News
Advertisement
The company has also launched a website for patients affected by hereditary angioedema, a rare genetic disorder.
Half of the 14 oncology indications approved in the second quarter were accelerated approvals.
This is the seventh approval for Erbitux and the only anti-EGFR antibody approved for this indication.
The enzyme replacement therapy treats Pompe disease, a rare genetic disorder that affects children.
The PDUFA target action date for the FDA decision is Jan. 30, 2022.
Data is being presented at the 10th Annual IDWeek Virtual Conference, September 29 to October 3.
AbbVie’s Qulipta is a once-daily oral to prevent migraines in adults.
The companies plan to request an emergency use authorization in a few weeks.
The companies are seeking accelerated approval based on the surrogate end point of beta amyloid reduction.
Advertisement
The flu program is the first in programs leveraging BioNTech’s mRNA technology for vaccines for other respiratory viruses, oncology, and genetic diseases.
Effective Jan. 1 2022, the move brings the price to 2008 levels.
Prices paid by Veterans Affairs were the lowest and were 50% to 60% below list prices.
The FDA assigned a Prescription Drug User Fee Act goal date of May 28, 2022.
Repatha is now available for children 10 and older to lower low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia.
The diabetes therapy is being recalled because of a lack of potency.
Amgen’s Biosimilar Trend Report finds that biosimilars have been introduced at a price that is generally 15% to 37% lower than the reference product.
Shifting cancer patients to the physician setting for administration of cancer therapies could save insurers $1.28 billion.
Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations.
This is the fourth approval for Jakafi, a JAK1/JAK2 inhibitor.
Keytruda plus chemotherapy reduces the risk of death by 27% in patients with triple-negative breast cancer.
People over the age 65 and those at high risk of severe COVID-19, including health care workers and those with occupational exposure, are eligible for the booster.
Dr. Reddy’s has also launched a generic of Librax. Recent generic approvals include clindamycin phosphate foam and sodium acetate.
Opzelura is the first and only topical formulation of a JAK inhibitor approved in the United States.
Tivdak is the first approved antibody-drug conjugate for the treatment of adult patients with recurrent or metastatic cervical cancer.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
3
Biosimilar competition could surpass IRA-negotiated savings by year three
4
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
5
